Search results for "Opiate"

showing 6 items of 26 documents

Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?

2014

The aim of this review was to update and summarize the scientific knowledge on the long term outcomes of the different pharmacological treatment options for opioid dependence currently available and to provide a critical discussion on the different treatment options based on these results. We performed a literature search using the PubMed databases and the reference lists of the identified articles. Data from research show that the three pharmacological options reviewed are effective treatments for opioid dependence with positive long term outcomes. However, each one has its specific target population and setting. While methadone and buprenorphine are first line options, heroin-assisted tre…

Pharmacologymedicine.medical_specialtybusiness.industryTreatment optionsOpiate Substitution TreatmentHeroinHeroin-assisted treatmentOpioidmedicineLong term outcomesPharmacology (medical)businessPsychiatrymedicine.drugMethadoneBuprenorphineBritish Journal of Clinical Pharmacology
researchProduct

Assessment and treatment of the withdrawal syndrome in paediatric intensive care units

2020

Background: Sedoanalgesia secondary iatrogenic withdrawal syndrome (IWS) in paediatric intensive units is frequent and its assessment is complex. Therapies are heterogeneous, and there is currently no gold standard method for diagnosis. In addition, the assessment scales validated in children are scarce. This paper aims to identify and describe both the paediatric diagnostic and assessment tools for the IWS and the treatments for the IWS in critically ill paediatric patients. Methods: A systematic review was conducted according to the PRISMA guidelines. This review included descriptive and observational studies published since 2000 that analyzed paediatric scales for the evaluation of the i…

TreatmentAssessment toolsOpiatesIatrogenic withdrawal syndromeSedativesPaediatric intensive care units
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

2020

International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…

medicine.medical_specialtyDoseNarcotic Antagonists[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthReceptors Opioid mu030226 pharmacology & pharmacyPartial agonistOpioid dependenceDependance aux opioides03 medical and health sciencesSubcutaneous injection0302 clinical medicineProlonged releasemedicineHumansProlonged-releasePharmacology (medical)OpiacésAction prolongeebusiness.industryOpioid use disorderOpioid-Related Disordersmedicine.disease3. Good healthBuprenorphineAnalgesics OpioidOpiatesOpioid[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthEmergency medicinebusinessSubstitutionMethadoneBuprenorphinemedicine.drugMethadone
researchProduct

Therapies in early development for the treatment of opiate addiction.

2015

Opiate drugs are psychoactive substances used to manage severe pain. However, their chronic use is associated with the development of addiction. Opiate addiction represents a significant public health concern.This review focuses on the most recent advances in the pharmacological treatment of opiate addiction, from those being tested in clinical trials (Phase I and II), to preclinical studies that point to new targets. Readers will gain knowledge of the wide variety of treatments used to treat opiate addiction, including their strengths and weaknesses, and the promising pharmacological targets identified by preclinical research.Among the currently available agonist therapies, new dosage form…

medicine.medical_specialtymedia_common.quotation_subjectNarcotic AntagonistsNaltrexonePharmacological treatmentmedicineAnimalsHumansPharmacology (medical)Molecular Targeted TherapyPsychiatrymedia_commonPharmacologybusiness.industryAddictionGeneral MedicineOpioid-Related DisordersNaltrexoneBuprenorphineClinical trialAnalgesics OpioidDrug DesignOpiate addictionOpiatebusinessmedicine.drugMethadoneBuprenorphineExpert opinion on investigational drugs
researchProduct

Assessment and treatment of the withdrawal syndrome in paediatric intensive care units

2020

Supplemental Digital Content is available in the text

medicine.medical_specialtymedicine.drug_classIatrogenic DiseaseMEDLINEIntensive Care Units PediatricSedoanalgesia03 medical and health sciences0302 clinical medicinepaediatric intensive care unitsassessment toolsmedicineHumansopiates030212 general & internal medicineDexmedetomidineChildIntensive care medicineBenzodiazepinetreatmentbusiness.industrysedativesGold standardGeneral Medicine6200Substance Withdrawal SyndromeClonidine030220 oncology & carcinogenesisComputingMethodologies_DOCUMENTANDTEXTPROCESSINGObservational studyiatrogenic withdrawal syndromebusinessSystematic Review and Meta-AnalysisResearch Articlemedicine.drugMethadoneMedicine
researchProduct